| Literature DB >> 30808927 |
Susan E Maloney1,2,3, Carla M Yuede1,4, Catherine E Creeley5, Sasha L Williams1, Jacob N Huffman1, George T Taylor2, Kevin N Noguchi1,3, David F Wozniak6,7,8.
Abstract
Epidemiological studies suggest exposures to anesthetic agents and/or sedative drugs (AASDs) in children under three years old, or pregnant women during the third trimester, may adversely affect brain development. Evidence suggests lengthy or repeated AASD exposures are associated with increased risk of neurobehavioral deficits. Animal models have been valuable in determining the type of acute damage in the developing brain induced by AASD exposures, as well as in elucidating long-term functional consequences. Few studies examining very early exposure to AASDs suggest this may be a critical period for inducing long-term functional consequences, but the impact of repeated exposures at these ages has not yet been assessed. To address this, we exposed mouse pups to a prototypical general anesthetic, isoflurane (ISO, 1.5% for 3 hr), at three early postnatal ages (P3, P5 and P7). We quantified the acute neuroapoptotic response to a single versus repeated exposure, and found age- and brain region-specific effects. We also found that repeated early exposures to ISO induced subtle, sex-specific disruptions to activity levels, motor coordination, anxiety-related behavior and social preference. Our findings provide evidence that repeated ISO exposures may induce behavioral disturbances that are subtle in nature following early repeated exposures to a single AASD.Entities:
Year: 2019 PMID: 30808927 PMCID: PMC6391407 DOI: 10.1038/s41598-019-39174-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Age at greatest vulnerability to increased apoptosis induced by ISO in the developing mouse brain is region-specific. Mouse pups were exposed to 1.5% ISO or AIR only for 3 h on P3, P5, or P7, and processed for AC3+ IHC beginning 6 h after initiation of exposure. Representative AC3+ IHC images of mouse pup brain at the ages at which the greatest increase in apoptotic neurodegenerative response induced by ISO above typical developmental levels (AIR) was observed. Thalamus, P3; Hippocampus, P5; Striatum, P5; Cortex; P5. Scale bar is 50 µm.
Statistical results of AC3+ IHC quantification in brains of ISO- and AIR-exposed mouse pups.
| Age At Exposure | rmANOVA interaction | Within Region Comparisons (Drug) | |||
|---|---|---|---|---|---|
| Region × Drug | Cortex | Thalamus | Striatum | Hippocampus | |
| P3 | |||||
| P5 | |||||
| P7 | |||||
| P7, P5+7, P3+5+7 |
| ||||
All distributions were normal and p-values reflect Bonferroni correction.
Figure 2Neonatal ISO exposure increased the density of AC3+ profiles following single and multiple exposures in an age-dependent manner. Mouse pups were exposed to 1.5% ISO for 3 h or AIR only on P3, P5, P7, P5+7 or P3+5+7 and the density of AC3+ profiles was quantified in four distinct brain regions. (A) At P3, increased AC3+ densities were observed in the thalamus only of ISO-exposed brains compared to AIR-exposed controls. (B) At P5, an increase in AC3+ densities was observed in all brain regions examined. (C) At P7, increased AC3+ densities were observed only in the cortex of ISO-exposed brains compared to AIR-exposed controls. (D) In the cortex, enhanced AC3+ densities were observed following ISO exposure on P7, P5+7, and P3+5+7 compared to AIR only exposure. No change in AC3+ density over AIR controls was observed in the thalamus at P7 regardless of number of exposures. Only following ISO exposure on P5+7 were increased AC3+ densities observed in the striatum and hippocampus over AIR controls. Means ± SEM are shown. All data points represented by open gray circles.
Order of and age at testing to evaluate behavioral effects of multiple neonatal ISO exposures.
| Behavioral Tests | Age At Testing |
|---|---|
| 1- h locomotor activity | P31/P137 |
| Sensorimotor battery | P32–33 |
| Morris water maze | P34–42 |
| Rotarod | P45, P49, P53 |
| Elevated plus maze | P54–56/P144–146 |
| Social approach | P60/P178 |
| Conditioned fear | P194–196 |
Figure 3Multiple neonatal ISO exposures results in subtle, sex-specific behavioral disruptions. Male and female mice were exposed to 1.5% ISO for 3 h or AIR only on P3+5+7 and behaviorally characterized across multiple domains beginning during the juvenile stage and continuing into adulthood. (A,B) During the 1-h locomotor activity/exploration test, male, but not female, ISO mice exhibited (A) decreased total ambulations across the six 10-min blocks (*p = 0.031) and (B) increased total time at rest. (C) ISO mice spent less time on the accelerating rotarod during the first trial on Day 2 and second trial on Day 3 compared to AIR mice (*p = 0.003, Day 3). (D) These deficits were most pronounced between male mice (*p = 0.012, Day 3). (E,F) Male ISO mice spent less (E) absolute (*p = 0.028) and (F) percent total time in the open arms (*p = 0.032) of the EPM compared to male AIR mice. Female mice displayed comparable EPM performance across groups. (G) During the preference for social novelty trial of the social approach task, both male ISO and AIR mice exhibited a preference to spend more time investigating the novel conspecific and female AIR mice exhibited a trend for this preference, while female ISO mice spent a similar amount of time investigating both the familiar and novel conspecifics. (H) Only male AIR mice exhibited a greater number of entries into the investigation zone around the novel mouse compared to that around the familiar mouse. Means ± SEM are shown. All data points represented by open gray circles.
Statistical results of behavioral testing of ISO- and AIR-exposed mice.
| Variable | Comparison | Statistical test | Output | P value | Nonparametric |
|---|---|---|---|---|---|
| Total ambulations (across 10-min blocks) | Drug | two-way rmANOVA | normal | ||
| Males only, Drug | rmANOVA | normal | |||
| Females only, Drug | rmANOVA | normal | |||
| Rearing (across 10-min blocks) | Drug | two-way rmANOVA | normal | ||
| Males only, Drug | rmANOVA | n/a | |||
| Females only, Drug | rmANOVA | normal | |||
| Time at rest | Drug | two-way ANOVA | normal | ||
| Male only, Drug | ANOVA | normal | |||
| Females only, Drug | ANOVA | normal | |||
| Time in center area | Drug | two-way ANOVA | normal | ||
| Males only, Drug | ANOVA | normal | |||
| Females only, Drug | ANOVA | normal | |||
| Entries into center area | Drug | two-way ANOVA | normal | ||
| Males only, Drug | ANOVA | normal | |||
| Females only, Drug | ANOVA | ||||
| Accelerating rotarod (across 3 days/6 trials) | Drug × Day | two-way rmANOVA | n/a | ||
| Day 2, Drug | multiple comparison | ||||
| Day 3, Drug | multiple comparison | ||||
| Males only, Drug × Day | rmANOVA | normal | |||
| Males only, Day 2, Drug | multiple comparison | ||||
| Males only, Day 3, Drug | multiple comparison | normal | |||
| Females only, Drug × Day | rmANOVA | normal | |||
| Females only, Day 2, Drug | multiple comparison | ||||
| Females only, Day 3, Drug | multiple comparison | normal | |||
| Time in open arm (across 3 days) | Drug | two-way rmANOVA | n/a | ||
| Males only, Drug | rmANOVA | n/a | |||
| Females only, Drug | rmANOVA | normal | |||
| Percent time in open arm (across 3 days) | Drug | two-way rmANOVA | n/a | ||
| Day × Sex | two-way rmANOVA | n/a | |||
| Males only, Drug | rmANOVA | n/a | |||
| Females only, Drug | rmANOVA | normal | |||
| Sociability, investigation zone time (social vs. empty) | Drug × Zone | two-way rmANOVA | n/a | ||
| AIR, Zone | planned comparison | ||||
| ISO, Zone | planned comparison | normal | |||
| AIR males only, Zone | planned comparison | ||||
| AIR females only, Zone | planned comparison | normal | |||
| ISO males only, Zone | planned comparison | normal | |||
| ISO females only, Zone | planned comparison | normal | |||
| Sociability, investigation zone entries (social vs. empty) | Drug × Zone | two-way rmANOVA | normal | ||
| AIR, Zone | planned comparison | normal | |||
| ISO, Zone | planned comparison | normal | |||
| AIR males only, Zone | planned comparison | normal | |||
| AIR females only, Zone | planned comparison | normal | |||
| ISO males only, Zone | planned comparison | normal | |||
| ISO females only, Zone | planned comparison | normal | |||
| Social novelty, investigation zone time (familiar vs. novel) | Drug × Zone | two-way rmANOVA | n/a | ||
| Sex × Zone | two-way rmANOVA | normal | |||
| AIR, Zone | planned comparison | normal | |||
| ISO, Zone | planned comparison | ||||
| AIR males only, Zone | planned comparison | normal | |||
| AIR females only, Zone | planned comparison | normal | |||
| ISO males only, Zone | planned comparison | ||||
| ISO females only, Zone | planned comparison | normal | |||
| Social novelty, investigation zone entries (familiar vs. novel) | Drug × Zone | two-way rmANOVA | normal | ||
| Sex × Zone | two-way rmANOVA | normal | |||
| AIR, Zone | planned comparison | normal | |||
| ISO, Zone | planned comparison | normal | |||
| AIR males only, Zone | planned comparison | normal | |||
| AIR females only, Zone | planned comparison | normal | |||
| ISO males only, Zone | planned comparison | normal | |||
| ISO females only, Zone | planned comparison | normal | |||
| Males only, Novel Zone, Drug | multiple comparison | normal |
For non-normal distributions, Mann-Whitney U and Wilcoxon Signed-Ranks nonparametric tests for two independent and paired samples, respectively, are also reported. Equivalent nonparametric test for two-way rmANOVA not available (n/a). Bonferroni correction reflected in p-values, where appropriate.